Leo Wealth LLC Buys 60,136 Shares of Pfizer Inc. $PFE

Leo Wealth LLC bought a new position in Pfizer Inc. (NYSE:PFE) in the 3rd quarter, Holdings Channel.com reports. The firm bought 60,136 shares of the biopharmaceutical company’s stock, valued at approximately $1,715,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Retirement Wealth Solutions LLC boosted its holdings in shares of Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 509 shares in the last quarter. Keb Asset Management LLC bought a new position in shares of Pfizer during the 2nd quarter valued at about $26,000. Field & Main Bank purchased a new position in shares of Pfizer during the 2nd quarter valued at about $27,000. Evolution Wealth Management Inc. raised its holdings in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 566 shares in the last quarter. Finally, Bullseye Investment Management LLC purchased a new position in shares of Pfizer during the 2nd quarter valued at about $28,000. Institutional investors own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded approval of TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for men with metastatic hormone-sensitive prostate cancer whose tumors have homologous recombination repair (HRR) gene mutations, including BRCA and non-BRCA mutations. Moving the treatment into an earlier stage of metastatic disease could enlarge the addressable patient population and support future sales growth. Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
• Positive Sentiment: Pfizer also reported Phase 2 results across serotypes for its 25-valent pneumococcal conjugate vaccine candidate, 25vPnC. The update adds visibility to the company’s vaccine pipeline, though the available report does not provide enough detail to assess the results’ commercial significance. Pfizer announces results across serotypes in Phase 2 study of 25vPnC
• Neutral Sentiment: Pfizer’s shares have gained about 29.7% over the past year and are near their 52-week high, prompting discussion over whether the valuation is ahead of the company’s earnings growth. Investors may require further pipeline or operating improvements to justify additional gains. Pfizer Stock Looks Above Fair Value As 30% Run Continues
• Neutral Sentiment: Pfizer was relatively resilient while Moderna and BioNTech declined amid disappointment over cancer-vaccine trial data. The comparison may offer some support for PFE, but it does not directly change Pfizer’s fundamentals. Moderna Tumbles as Cancer Vaccine Selloff Deepens
• Negative Sentiment: Broader healthcare stocks traded lower, creating sector-level pressure on Pfizer. Separately, an experimental Pfizer lung-cancer drug showed a survival benefit in some patients despite a failed trial, leaving its development outlook uncertain rather than providing a clear catalyst. Healthcare Stocks Softer Monday

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PFE. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. JPMorgan Chase & Co. increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 9th. Bank of America decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Scotiabank boosted their price objective on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Finally, BMO Capital Markets lowered their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Five research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus price target of $28.72.

Pfizer Stock Performance

Shares of PFE stock opened at $29.80 on Tuesday. The company has a market capitalization of $169.82 billion, a P/E ratio of 39.20, a PEG ratio of 2.04 and a beta of 0.32. Pfizer Inc. has a fifty-two week low of $23.62 and a fifty-two week high of $30.44. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The stock has a 50 day moving average price of $28.30 and a two-hundred day moving average price of $26.67.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter last year, the business earned $0.78 earnings per share. The business’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a yield of 5.8%. Pfizer’s dividend payout ratio is presently 226.32%.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.